Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 5, 2009, Pages 337-339

  Talamo, Giampaolo P ^a   Ibrahim, Sulfi ^a   Claxton, David ^a   Tricot, Guido J ^c   Fink, Louis M ^b   Zangari, Maurizio ^c,d  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b NEVADA CANCER INSTITUTE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d NONE   (United States)

Author keywords

Deep vein thrombosis; Multiple myeloma; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CISPLATIN; CLOPIDOGREL; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ETOPOSIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; WARFARIN;

ANTITHROMBIN DEFICIENCY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; LABORATORY TEST; LEG THROMBOSIS; LUNG EMBOLISM; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; RETROSPECTIVE STUDY; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ANGIOGENESIS INHIBITORS; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FACTOR V; FOLLOW-UP STUDIES; HUMANS; HYPERHOMOCYSTEINEMIA; MULTIPLE MYELOMA; PREDNISONE; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; THALIDOMIDE; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 68149084935     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832b27e6     Document Type: Article

References (8)

1. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98:1614-1615.
2. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-19.
3. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17:775-779.
4. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1:445-449.
5. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003; 29:275-282.
6. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503-1506.
7. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
8. Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol 1999; 62:99-102.